Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(3.53)
# 910
Out of 5,116 analysts
87
Total ratings
45.05%
Success rate
7.55%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIST Milestone Pharmaceuticals | Maintains: Buy | $5 → $8 | $2.08 | +284.62% | 3 | Dec 15, 2025 | |
| PTHS Pelthos Therapeutics | Initiates: Buy | $60 | $25.71 | +133.37% | 1 | Dec 3, 2025 | |
| TRAW Traws Pharma | Initiates: Buy | $8 | $1.17 | +583.76% | 1 | Dec 3, 2025 | |
| CRDL Cardiol Therapeutics | Reiterates: Buy | $9 | $0.99 | +806.25% | 2 | Dec 1, 2025 | |
| CRMD CorMedix | Maintains: Buy | $17 → $18 | $12.53 | +43.66% | 4 | Nov 13, 2025 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $44 → $46 | $49.84 | -7.70% | 7 | Nov 7, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $10 | $7.37 | +35.69% | 3 | Nov 7, 2025 | |
| INDV Indivior | Maintains: Buy | $28 → $35 | $36.21 | -3.34% | 2 | Oct 30, 2025 | |
| RANI Rani Therapeutics Holdings | Assumes: Buy | $11 | $1.40 | +685.71% | 3 | Oct 21, 2025 | |
| OMER Omeros | Maintains: Buy | $9 → $20 | $15.71 | +27.31% | 3 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $5.79 | +89.98% | 6 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.24 | +706.45% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $82.40 | +46.84% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $8.41 | +114.03% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $7.92 | +64.14% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.49 | +167.56% | 2 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $7.55 | +58.94% | 3 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.07 | +219.41% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.69 | +160.22% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $29 | $5.96 | +386.58% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $16.85 | +18.69% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $8.87 | +193.12% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.28 | +368.75% | 2 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $12.85 | +63.42% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $0.86 | +478.30% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.23 | +3,340.86% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $12.43 | +28.72% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $14.10 | +3,126.95% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $24.22 | +143.60% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $170.48 | +5.58% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.40 | +9,066.67% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $28.49 | +12.32% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.14 | +1,929,724.56% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $11.15 | +348.43% | 1 | Jul 12, 2018 |
Milestone Pharmaceuticals
Dec 15, 2025
Maintains: Buy
Price Target: $5 → $8
Current: $2.08
Upside: +284.62%
Pelthos Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $60
Current: $25.71
Upside: +133.37%
Traws Pharma
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $1.17
Upside: +583.76%
Cardiol Therapeutics
Dec 1, 2025
Reiterates: Buy
Price Target: $9
Current: $0.99
Upside: +806.25%
CorMedix
Nov 13, 2025
Maintains: Buy
Price Target: $17 → $18
Current: $12.53
Upside: +43.66%
Collegium Pharmaceutical
Nov 7, 2025
Maintains: Buy
Price Target: $44 → $46
Current: $49.84
Upside: -7.70%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Buy
Price Target: $10
Current: $7.37
Upside: +35.69%
Indivior
Oct 30, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $36.21
Upside: -3.34%
Rani Therapeutics Holdings
Oct 21, 2025
Assumes: Buy
Price Target: $11
Current: $1.40
Upside: +685.71%
Omeros
Oct 15, 2025
Maintains: Buy
Price Target: $9 → $20
Current: $15.71
Upside: +27.31%
Oct 13, 2025
Reiterates: Buy
Price Target: $11
Current: $5.79
Upside: +89.98%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.24
Upside: +706.45%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $82.40
Upside: +46.84%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $8.41
Upside: +114.03%
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $7.92
Upside: +64.14%
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $4.49
Upside: +167.56%
Aug 20, 2025
Reiterates: Buy
Price Target: $12
Current: $7.55
Upside: +58.94%
Aug 13, 2025
Reiterates: Buy
Price Target: $13
Current: $4.07
Upside: +219.41%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.69
Upside: +160.22%
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $5.96
Upside: +386.58%
Jul 28, 2025
Assumes: Buy
Price Target: $20
Current: $16.85
Upside: +18.69%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $8.87
Upside: +193.12%
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.28
Upside: +368.75%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $12.85
Upside: +63.42%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.86
Upside: +478.30%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.23
Upside: +3,340.86%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $12.43
Upside: +28.72%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $14.10
Upside: +3,126.95%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $24.22
Upside: +143.60%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $170.48
Upside: +5.58%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.40
Upside: +9,066.67%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $28.49
Upside: +12.32%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.14
Upside: +1,929,724.56%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $11.15
Upside: +348.43%